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Abstract
Treatment of Chagas disease with nifurtimox requires age- and body weight-adjusted dosing, resulting in complex dosing
instructions. Appropriate formulations are needed for precise and compliant dosing, especially in pediatric patients. We
characterized the biopharmaceutical features of a standard nifurtimox 120-mg tablet and a 30-mg tablet developed to
improve dose accuracy. Two open-label, randomized crossover studies were conducted in adult outpatients with Chagas
disease.One study investigated whether 4 × 30-mg tablets and 1 × 120-mg tablet were bioequivalent and whether tablets
can be administered as an aqueous slurry without affecting bioavailability. The second study investigated the effect of
a high-calorie/high-fat diet versus fasting on the absorption of nifurtimox after a single 4 × 30-mg dose. Interventions
were equivalent if the 90% confidence interval (CI) of their least-squares (LS) mean ratios for both AUC0-tlast and Cmax
were in the range of 80%-125%. The 4 × 30-mg and 1 × 120-mg tablet doses were bioequivalent (AUC0-tlast : LS mean
ratio, 104.7%; 90%CI, 99.1%-110.7%; Cmax : LS mean ratio, 101.7%; 90%CI, 89.4%-115.6%; n = 24). Exposure when giving
the 4 × 30-mg dose as a slurry or as tablets was comparable, with an AUC0-tlast ratio of 93.2% (84.2%-103.1%; n = 12)
and a slightly decreased Cmax ratio for the slurry of 76.5% (68.8%-85.1%). Food improved the bioavailability of nifurtimox
substantially (AUC0-tlast ratiofed/fasted , 172%; 90%CI, 154%-192%; Cmax ratiofed/fasted , 168%; 90%CI, 150%-187%). The data
indicate that the 30- and 120-mg tablets are suitable for dosing adult and pediatric patients accurately; nifurtimox should
be administered under fed conditions.
Keywords
bioavailability, exposure, fasting, food effect, Trypanosoma cruzi, water dispersible

Chagas disease is a chronic and potentially lifethreatening disease caused by the parasite Trypanosoma
cruzi.1 The main route of human transmission is contamination of a bite site or of mucous membranes with
parasite-containing feces from carrier insects.1 Vectorborne transmission is generally limited to North, South,
and Central America,1 whereas transplacental infection
is the main route in nonendemic countries.2 Since the
early 1990s, several South American countries have focused on eradicating the main insect vector of Chagas disease.3 Currently, vector transmission is partially
controlled, and most of the new cases occur in urban areas through congenital transmission.4 A study
was conducted in 2008 in 12 776 children aged 1-5
years in contiguous rural areas in which uninterrupted
vector-control measures had been in place since 1999.
The study determined that the seroprevalence rate of
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Figure 1. The chemical structure of nifurtimox (CAS No.23256-30-6;molecular weight,287.29 g/mol) and reduction of the nitrofuran
by type I nitroreductase to generate a hydroxylamine via a nitroso intermediate. The hydroxylamine can be metabolized further to
form a nitrenium cation (that can promote DNA breakage), the amine form, or unsaturated and then saturated open-chain nitriles
(that could react nonspecifically with a range of cellular components). Reproduced and adapted from Hall et al, J Biol Chem 20117 ).

Chagas disease in this pediatric population was 0.24%
and was attributable to vertical transmission of the
parasite.3 In comparison, a 2019 study of children in
an area in Bolivia in which vector control is inherently
problematic determined that seroprevalence was 22%
overall and increased dramatically with age owing to
persistent vector transmission.5
Nifurtimox (Figure 1) is 1 of only 2 antitrypanosomal agents available for the treatment of Trypanosoma
cruzi infection.6 Antiparasitic treatment during the
acute phase of the infection is estimated to be 80%90% curative, including in early cases of congenital
transmission.1 The cytotoxicity of nifurtimox in Trypanosoma cruzi has been attributed to metabolism by a
type I nitroreductase that leads to production of nitrenium ions, which promote DNA strand breaks, and of
saturated open-chain nitriles that can react nonspecifically with a range of cellular components (Figure 1).7
The type I enzyme is rarely found in eukaryotes, except
for trypanosomes,8 and has no catalytic requirement for
oxygen. The analogous mechanism in humans involves
a type II nitroreductase that, in the presence of oxygen,

converts nifurtimox to an intermediate that undergoes
futile cycling, regenerating the parent compound and
releasing superoxide anions.7
Pharmacokinetic (PK) studies in animals and in humans indicate that nifurtimox is rapidly absorbed from
the gastrointestinal tract, with peak concentrations
reached after ≈2 hours.9,10 From animal investigations,
it has been concluded that concentrations in blood and
in the majority of the organs and tissues are similar.9
Nifurtimox passes the placental and blood-brain
barriers,9 and breastfeeding while taking nifurtimox
is not recommended owing to its excretion in breast
milk.11 However, a population PK model estimate,11
subsequently corroborated by a clinical study,12 determined that nifurtimox levels in breast milk are
typically <10% of the maternal weight-adjusted dose
and below the levels to which infants being treated
with nifurtimox would typically be exposed.11,12 The
drug is rapidly and extensively metabolized,13 but the
metabolic pathways have not been elucidated. It is
known that nitroreductases play an important role in
the metabolism of nitrofurans such as nifurtimox,14
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but detailed characterization of its main metabolites
in humans is yet to be reported. Nifurtimox is eliminated with a half-life of ≈3 hours,10 and only 0.5%
is excreted unchanged in urine.13 However, following
oral and intravenous administration of radiolabeled
nifurtimox in animals, ≈40% of the radioactive dose
was recovered in urine.9 To date, there has been no
published investigation of biliary and fecal elimination
of nifurtimox or of its metabolites in humans.
In terms of the safety profile of nifurtimox, a
study of 53 patients with Chagas disease receiving
nifurtimox reported anorexia, nausea, headache, amnesia, and weight loss as the most common events.15
Another study that compared adverse reactions across
different study cohorts receiving nifurtimox determined
that digestive disturbances, neurologic toxicity, psychiatric symptoms, and skin hypersensitivity reactions
were generally the most common events.16 No drugdrug interactions have been described for nifurtimox,
although warnings include the potential for significant
adverse side effects with concomitant use of alcohol;
studies in rodents indicated that this may be attributable
to induction of hepatic P450 reductase, leading to increased nitroreduction of nifurtimox.17
The drug is currently supplied as a 120-mg oral tablet
to be taken with food18 ; in children and adolescents
the therapeutic dose must be adjusted for age and body
weight to account for differences in biodistribution and
stages of organ maturation.6 The total recommended
daily dose of nifurtimox in infants and children aged
not greater than 10 years and weighing up to 32 kg is
from 10 mg/kg up to a maximum of 20 mg/kg body
weight.18 In adolescents (aged 11-16 years) weighing up
to 60 kg, the daily dose is 12.5-15 mg/kg body weight,
and in adults (aged ≥17 years) the daily dose is 810 mg/kg. Dosing in adults weighing less than 60 kg
should also be in the range of 8-10 mg/kg, and dosing must be adjusted during treatment if a patient loses
weight.18 The total daily dose is administered in 3 separate doses (morning, noon, and evening), each after
food intake.18 Typically the nifurtimox dosing regimen
is maintained for at least 60 days.19
This relatively complex dosing scheme must be translated into a treatment regimen by individuals often lacking medical training and with limited resources. The
existing 120-mg tablets are scored to facilitate division
into two 60-mg fragments, but further subdivision is
commonly necessary, especially for children. Administration of multiple small tablet fragments is prone to
inaccurate dosing and to compliance problems among
individuals of low or even intermediate body weight.
Swallowing tablets can also be difficult for some patients and is not well suited to very young children and
infants in whom there is a heightened risk of tablet fragment aspiration.20,21
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Accuracy of dosing, and thus compliance, could be
improved if tablets delivering a dose < 120 mg were
available. The availability of different dose strengths
of readily divisible tablets may also simplify preparation of each dose, which would be preferable from
both administration and compliance perspectives and
would yield precise dose increments across all ranges
of age and body weight. Tablets that can be dispersed
readily as an aqueous slurry address swallowing issues and obviate the need for separate liquid pediatric
formulations or administration devices. Accordingly,
a divisible 30-mg nifurtimox tablet was developed to
complement the existing divisible 120-mg tablet. Access to both tablet doses and the option to disperse
tablets in water could improve dose accuracy in all age
groups and body weights, including dose-appropriate
treatment of children with low body weight. Improving
dose accuracy and encouraging compliance are likely
to have positive implications for safety and patient
outcomes.
The aims of the 2 studies reported here were to
compare the bioavailability and PK of a new 30-mg
nifurtimox tablet administered whole or as an aqueous
slurry with those of a 120-mg tablet (study A) and to
examine the impact of food on the absorption of these
formulations (study B). Both studies also examined the
safety and tolerability of nifurtimox.

Methods
Study protocols and informed consent documentation
were approved by an independent ethics committee (Independent Ethics Committee for Clinical Pharmacology Research, Buenos Aires, Argentina). The studies
were conducted in accordance with the ethical principles of the Declaration of Helsinki and in compliance
with the International Conference on Harmonization
Good Clinical Practice guidelines. All participants gave
written informed consent before enrollment. The studies were conducted at FP Clinical Pharma SRL, Buenos
Aires, Argentina.

Study Designs
Study A was a phase 1 single-center, open-label, randomized, 3-intervention crossover study designed to assess the bioequivalence of the novel 30-mg oral tablet
and the currently marketed 120-mg tablet under fed
conditions in adult patients with Chagas disease and
to characterize the PK of nifurtimox after ingestion
as an aqueous slurry. The study was conducted between November 2013 and September 2014 (ClinicalTrials.gov Identifier: NCT01927224).
Study B was a phase 1 single-center, open-label, randomized crossover study conducted between December
2015 and August 2016 (ClinicalTrials.gov Identifier:
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NCT02606864) to investigate the effect of a highcalorie, high-fat meal versus a fasting state on the PK of
four 30-mg nifurtimox tablets administered as a single
dose to adult patients with Chagas disease. Both studies
also examined the safety and tolerability of nifurtimox.
The 2 studies each had an initial 4-week screening
period followed by 2 treatment periods that were separated by a washout of at least 5 days. Participants
arrived 12 hours before dosing and remained at the
study center for 24 hours after dosing. Doses were
swallowed immediately after a high-fat, high-calorie
breakfast (unless patients were fasting [study B]) with
≈240 mL of water while the participant was in a sitting
position. The participant then remained supine for 4
hours postdose; water intake was not permitted for
2 hours postdose. Further meals on treatment days were
standardized and provided about 5, 8, and 10 hours
postdose, with subjects instructed to eat a normal diet
during the washout phase and in the follow-up period
(7-14 days after administration of the second dose). In
both studies, participants were assigned a randomization number after confirmation of eligibility at screening, and these numbers were randomly assigned to 1
of the 2 intervention sequences in their assigned group
according to a computer-generated randomization list.
Study A. In each treatment period, a total nifurtimox dose of 120 mg was administered 30 minutes
after a standardized high-fat, high-calorie breakfast
(1051 kcal) that was preceded by a fasting period of
at least 10 hours. Three interventions were specified:
(A) 4 nifurtimox 30-mg tablets taken whole with water;
(B) 4 nifurtimox 30-mg tablets dispersed in an aqueous
slurry; (C) 1 × nifurtimox 120-mg tablet taken whole
with water. Participants were randomized to 1 of 2 intervention sequences: in group 1 (tablet-slurry bioavailability), patients were randomized 1:1 to intervention
sequences A-B or B-A, and in group 2 (tablet bioequivalence) to sequences A-C or C-A (Figure 2A).
Study B. Two interventions were specified: (D) nifurtimox 120 mg (4 × 30-mg tablets) following a fasting
period of at least 10 hours; (E) nifurtimox 120 mg (4 ×
30-mg tablets) 30 minutes after a standardized highfat, high-calorie breakfast (800-1000 kcal) preceded by
a fasting period of at least 10 hours. Participants were
enrolled in 1 of 2 intervention sequences: D-E or E-D
(Figure 2B).
In both studies, blood and urine samples were taken
for safety analysis at baseline, after treatment, and at
follow-up. Blood samples were analyzed for hematology parameters; clotting status; clinical chemistry; hepatitis B, hepatitis C and human immunodeficiency virus
seroconversion; and pregnancy. Urinalysis parameters
included pH, hemoglobin, urobilinogen, erythrocytes,
protein, ketones, bilirubin, glucose, and urine sediment.
Blood samples for PK analysis were taken within 1 hour
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predose and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10,
12, 16, and 24 hours postdose. All samples were stored
at −20°C between collection and analysis and analyzed
within 116 days of sampling.

Study Participants
Studies A and B were conducted in patients in the indeterminate stage of Chagas disease who were otherwise
healthy, that is, no cardiac involvement or any other
pathology that could affect interpretation of the study
results. The diagnosis of chronic Chagas disease was
made by 2 positive serological tests for Trypanosoma
cruzi. Eligible patients were aged 18-45 years with a
body mass index (BMI) of at least 18 and no greater
than 29.9 kg/m2 . Women of childbearing age and sexually active men were required to use 2 methods of contraception during and for 12 weeks after completing
participation in a study. Full inclusion and exclusion
criteria for both studies are provided in the supplement
(Tables S1 and S2).

Safety and Tolerability Assessment
Adverse events (AEs) were defined as any untoward
medical occurrence in a participant after providing
written informed consent and were recorded throughout the study until the last follow-up visit; AEs were
summarized using Medical Dictionary for Regulatory Activities terms (version 19.0) and classified as
treatment-emergent AEs (TEAEs) if they first appeared
or worsened after the first dose of study drug and up to
30 days after the end of study treatment.

Nifurtimox Quantitation
Nifurtimox was assayed using liquid chromatography
with tandem mass spectrometry detection (inVentiv Health Clinical, Quebec City, Quebec, Canada).
Study samples of human plasma containing dipotassium ethylenediaminetetraacetate were thawed at
room temperature — 50 μL mixed with 100 μL of
the internal standard (nifurtimox-d8 ) and 500 μLof
assay buffer (500 mM 2-amino-2-[hydroxymethyl]1,3-propanediol). Samples underwent liquid-liquid
extraction by shaking with 4 mL of a 90/10 methyl
tert-butyl ether/hexane mixture for 15 minutes followed
by centrifugation at 2000g for 5 minutes at room temperature. Samples were flash-frozen in a methanol/dry
ice bath, and the organic phase removed to a new
tube and evaporated to dryness. Samples were reconstituted in methanol/water (46%/54%) containing 1
mM ammonium formate and 0.1% formic acid (also
the chromatography mobile phase) and separated isocratically at room temperature at 1 mL/min using a
Life Science ACE 3 C18 reversed-phase column (4.6 ×
30 mm, 3 μm) on an Agilent 1100 liquid chromatography system coupled to an Applied Biosystems/Sciex
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Screening

Treatment
period 1

Washout

Treatment
period 2

≥5 days

Day –28 to –1
Patients remained in
the study centre from
12 h before until
24 h after dosing

Patients remained in
the study centre from
12 h before until
24 h after dosing

Follow-up
4–7 days
post-treatment

Group 1
Intervention A: 4 x 30 mg nifurtimox tablets
Intervention B: 4 x 30 mg nifurtimox tablets dispersed as an
aqueous slurry
Treatment periods 1–2, patients randomized 1:1 to intervention
sequences:
A–B or B–A

Group 2
Intervention A: 4 x 30 mg nifurtimox tablets
Intervention C: 1 x 120 mg nifurtimox tablet
Treatment periods 1–2, patients randomized 1:1 to intervention
sequences:
A–C or C–A

(A)
Treatment period 1

Screening

Intervention D:
4 x 30 mg nifurtimox tablets
under fasted conditions

Treatment crossover

Washout

Treatment period 2
Intervention D:
4 x 30 mg nifurtimox tablets
under fasted conditions

≥5 days

Day –28 to –1
Intervention E:
4 x 30 mg nifurtimox tablets
under fed conditions (after
ingestion of high calorie/
high fat breakfast

Intervention E:
4 x 30 mg nifurtimox tablets
under fed conditions (after
ingestion of high calorie/
high fat breakfast

Follow-up
4–7 days
post-treatment

(B)
Figure 2. Study designs. (A) In study A, group 1 investigated the pharmacokinetic characteristics of nifurtimox administered as tablets
or slurry, and group 2 investigated the bioequivalence of the 30- and 120-mg tablets. Intervention sequences are shown in each group;
all dosing was under fed conditions. (B) Study B compared the bioavailability of nifurtimox under fed and fasting conditions.

API 4000 triple quadrupole mass spectrometer in positive TurboIonSpray ionization mode. After ionization
at atmospheric pressure the mass transition signals
of nifurtimox (288/148 amu; dwell time, 340 milliseconds) and the nifurtimox-d8 internal standard (296/156
amu; dwell time, 160 milliseconds) were recorded
using multiple-reaction monitoring. In study A the
interrun accuracy was −0.22% to 0.97% of bias, and
the interrun precision was 2.37%-4.09% of the coefficient of variation (CV) calculated from the quality
control samples. In study B, the interrun accuracy
was −1.30% to −3.33% of bias, and the inter-run

precision was 3.59%-5.48% of CV calculated from
quality control samples. Quantitation was by the
peak-area ratio method. Weighted (1/x2 ) linear regression was performed to determine the concentrations
of the analyte. All peak integrations were generated by Applied Biosystems/Sciex Analyst software
version 1.6.1, and all regressions were generated by
ThermoElectron Corporation Watson LIMS software, version 7.4.1. The calibration range (lower
limit of quantitation [LLOQ] to the upper limit) was
10-2000 μg/L. Only values above the LLOQ were
used to determine PK parameters. For both studies
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the concentration-time courses of nifurtimox were
prepared separately by intervention. Arithmetic and
geometric means, standard deviation (SD), median, and
% CV were calculated for each sampling point. Means
were only calculated if at least two-thirds of the individual data were measured and were above the LLOQ.

PK Calculations
The following primary PK parameters were calculated
based on the nifurtimox plasma concentration-overtime data: area under the concentration curve from
baseline to last measurable concentration (AUC0-tlast ),
maximum observed concentration (Cmax ), and time to
reach Cmax (tmax [study B]). Secondary PK parameters
included: area under the concentration curve (AUC),
Cmax normalized to dose and body weight (Cmax,norm ),
AUC from baseline to infinity normalized for dose/kg
body weight (AUCnorm [study A]), tmax , half-life associated with the terminal slope (t 1 ), and apparent total
2
body clearance (CL/F). In both studies, PK parameters
were calculated based on a model-independent noncompartmental method using WinNonlin (v.5.3; Pharsight Corporation/Certara, Princeton, New Jersey).

Statistical Analyses
A sample size of 12 subjects in study A group 1 was
considered adequate to compare the 2 modes of drug
ingestion (tablet vs aqueous slurry) descriptively and
to verify assumptions made about within-subject variability. In study A group 2, it was calculated that 21
participants would have 90% power to demonstrate the
bioequivalence of the 2 interventions (4 × 30-mg
tablets; 1 × 120-mg tablet) with respect to AUC0-tlast
and Cmax if, after a single dose of nifurtimox, the ratios of the least-squares (LS) means of these parameters in the 2 intervention groups were in the range
of 95%-105% (with 90% confidence intervals [CIs] for
both parameter ratios in the range of 80%-125% [specifically, the lower bound was ≥80.00% and the upper
bound ≤125.00%, when rounded to 2 decimal places])
and if the within-subject % CV for these parameters
was <18%. Enrollment of 24 individuals was planned
in study A group 2 to allow for possible study dropout.
For study B, it was calculated that a sample size of
32 participants would have 82% power (α = 0.05) to
rule out a food effect if the fed/fasted ratio for parameters AUC, AUC0-tlast , and Cmax were all in the range
of 95%-105% (with 90%CI for these ratios in the range
of 80%-125%), and the within-subject % CV for these
parameters was less than reference % CV values determined in study A (AUC0-tlast , 11.19; Cmax , 26.36). Target
recruitment of 36 individuals allowed for dropout.
Statistical analysis in both studies was performed using SAS (version 9.2; SAS Institute Inc., Cary, North
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Carolina). Analysis of bioequivalence in study A was
confirmatory; all other analyses were exploratory with
no adjustment for type I error. In study A, all individuals with at least 1 valid PK profile were included in the
PK analysis set. In study B, the PK analysis set comprised all individuals who completed both treatment periods with a valid set of PK samples. All individuals
who received at least 1 dose of study drug were included
in the safety set for both studies. Baseline demographic
and safety data in both studies were summarized descriptively.
For study A (groups 1 and 2), the AUC0-tlast
and Cmax of nifurtimox were analyzed assuming lognormally distributed data, using analysis of variance
(ANOVA) including sequence, subject (sequence), period, and treatment effects. Point estimates (LS means)
and exploratory 90%CIs for the ratios (group 1:
slurry/tablets; group 2: 4 × 30-mg tablets/1 × 120-mg
tablet) for AUC0-tlast and Cmax were calculated by
re-transformation of the logarithmic data using the
intraindividual SD of the ANOVA. For study B,
AUC, AUC0-tlast , and Cmax of nifurtimox were analyzed assuming log-normally distributed data, using
ANOVA including sequence, subject (sequence), period, and treatment effects. Point estimates (LS means)
and exploratory 90%CIs for the ratios (fed/fasted) for
AUC0-tlast and Cmax were calculated by retransformation of the logarithmic data using the intraindividual
SD of the ANOVA.

Results
Study A
PK Characteristics of Nifurtimox 120 mg Administered as
4 × 30-mg Tablets or as an Aqueous Slurry. Study A enrolled 39 individuals, of whom 37 were randomized;
1 randomized participant withdrew before receiving
study drug. All 36 individuals who received study drug
(group 1, n = 12; group 2, n = 24) completed the study
and were included in both the safety and PK analysis
sets; all participants in group 1 (12 of 12) and 66.7% in
group 2 (16 of 24) were women. Mean age, BMI, and
weight were similar in the 2 groups and in the intervention sequences within each group; all participants were
white (Table 1).
The arithmetic mean plasma concentrations of
nifurtimox over time in group 1 (receiving 120 mg
nifurtimox as 4 × 30-mg tablets or 4 × 30 mg as
an aqueous slurry) are shown in Figure 3A, and PK
parameters are summarized in Table 2 (geometric
mean plasma concentration of nifurtimox over time
in group 1 and geometric mean [% CV] group values
for PK parameters are shown in Figure S1A and
Table S3, respectively). Administered as an aqueous
slurry, nifurtimox had an AUC0-tlast similar to that

BMI, body mass index.
Study A: intervention A, 4 × 30-mg tablets; intervention B, 4 × 30 mg aqueous slurry; intervention C, 1 × 120-mg tablet (all dosing was under fed conditions). Study B: intervention D, 4 × 30-mg tablets,
fasted; intervention E, 4 × 30-mg tablets, fed.
a Mean (range); other data are mean ± standard deviation unless stated otherwise.

16 (88.9)
33.6 (26–43)
65.3 ± 10.9
26.9 ± 2.6
16 (88.9)
34.3 (27–45)
63.6 ± 10.7
25.7 ± 3.5
9 (75.0)
32.3 (22-45)
63.3 ± 11.4
24.2 ± 3.2
6 (100)
33.3 (22-42)
62.9 ± 4.4
25.8 ± 2.8
Women, n (%)
Age, yearsa
Weight, kg
BMI, kg/m2

6 (100)
34.3 (27-39)
66.8 ± 12.5
26.3 ± 2.5

12 (100)
33.8 (22-42)
64.9 ± 9.2
26.1 ± 2.5

7 (58.3)
32.5 (18-44)
64.5 ± 14.7
24.6 ± 3.4

16 (66.7)
32.4 (18-45)
63.9 ± 12.9
24.4 ± 3.2

E-D (n = 18)
C-A (n = 12)
B-A (n = 6)
A-B (n = 6)
Characteristic

Group 1

Total (n = 12)

A-C (n = 12)

Total (n = 24)

D-E (n = 18)

Study B
Group 2
Study A

Table 1. Patient Characteristics at Baseline by Study and Intervention Sequence

32 (88.9)
33.9 (26–45)
64.4 ± 10.7
26.3 ± 3.1

Clinical Pharmacology in Drug Development 2021, 10(5)
Total (n = 36)
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of the corresponding tablet formulation. The point
estimate (LS mean [90%CI]) ratio of 4 × 30 mg aqueous slurry versus 4 × 30-mg tablets for AUC0–tlast
was 93.2% (84.2%-103.1%) and for Cmax was 76.5%
(68.8%-85.1%). The 90%CIs for AUC0–tlast lay within
the predefined range for equivalent bioavailability, indicating no difference between the 2 intervention groups
in terms of systemic exposure to nifurtimox. When
administered as an aqueous slurry, peak exposure to
nifurtimox (Cmax ) was ≈24% lower than that achieved
with the same dose administered as tablets.
Equivalence of 4 × 30-mg and 1 × 120-mg Nifurtimox
Tablets. The arithmetic mean plasma concentrations
of nifurtimox over time in group 2 (receiving 4 × 30-mg
tablets or 1 × 120-mg tablet) are shown in Figure 3B,
and PK parameters are summarized in Table 2 (geometric mean plasma concentration of nifurtimox in
group 2, and the geometric mean [% CV] group values
for PK parameters are shown in Figure S1B and Table
S3, respectively). Median tmax was 4 hours with both
interventions, and the estimated arithmetic mean halflife in the 2 intervention groups differed by about 16
minutes. For the ratio of 4 × 30-mg tablets versus 1 ×
120-mg tablet, the point estimate (LS mean [90%CI])
ratio for AUC0-tlast was 104.7% (99.1%-110.7%) and
for Cmax was 101.7% (89.4%-115.6%). Bioequivalence
was demonstrated because the 90%CIs of the point
estimates for both parameters lay within the predefined
range (80%-125%).

Study B
Comparison of Bioavailability of Nifurtimox Administered as
4 × 30-mg Tablets Under Fed or Fasting Conditions. Study
B enrolled 39 individuals, of whom 36 were randomized
(sequence D-E, n = 18; sequence E-D, n = 18). One participant randomized to the E-D (fed-fasted) intervention sequence discontinued, withdrawing consent after
the first dose of study drug. All 36 participants were
included in the safety set; the 35 individuals who completed the study were included in the PK set. Participants in both intervention sequences were well matched
by sex, age, and weight. Most participants were female
(88.9%; n = 36) and Hispanic or Latino (91.7%; n =
33); all were white.
The arithmetic mean plasma concentrations of
nifurtimox over time in the groups receiving 4 × 30mg tablets under fasted (group D) or fed (group E)
conditions are shown in Figure 4, and PK parameters
are summarized in Table 3 (geometric mean plasma
concentration of nifurtimox over time in groups D and
E, and the geometric mean [% CV] group values for
PK parameters are shown in Figure S2 and Table S4,
respectively). Food taken before dosing increased systemic exposure to nifurtimox by at least 71% compared
with fasting conditions. The estimated ratios (LS mean
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Figure 3. Nifurtimox plasma concentrations for participants in study A. (A) Group 1: 4 × 30-mg tablets or 4 × 30-mg aqueous
slurry under fed conditions (n = 12), (B) group 2: 4 × 30-mg tablets or 1 × 120-mg tablet under fed conditions (n = 24). Data are
arithmetic mean and standard deviation. LLOQ, lower limit of quantitation.
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Table 2. Pharmacokinetic Parameters of Nifurtimox in Study A (Mean ± SD; PK Analysis Set)a
Group 1

Parameter

Group 2

Intervention A: 4 ×
30-mg Tablets (n = 12)

Intervention B: 4 × 30-mg
Aqueous Slurry (n = 12)

Intervention A: 4 ×
30-mg Tablets (n = 24)

Intervention C: 1 ×
120-mg Tablet (n = 24)

2830 ± 542
2720 ± 535
1510 ± 233
586 ± 158
309 ± 59.2
4.0 (2.0-6.0)
3.32 ± 0.39

2680 ± 526
2550 ± 519
1440 ± 315
450 ± 114
240 ± 56.8
4.0 (2.0-8.0)
3.88 ± 1.94

2750 ± 710
2640 ± 693
1420 ± 265
552 ± 186
287 ± 99.8
4.0 (2.0-6.0)
2.69 ± 0.56

2620 ± 607
2520 ± 594
1350 ± 242
540 ± 178
282 ± 99.2
4.0 (2.0-6.0)
2.96 ± 0.78

AUC, μg·h/L
AUC0–tlast , μg·h/L
AUCnorm , μg·h/L
Cmax , μg/L
Cmax,norm , kg/L
tmax , ha
t1 , h
2

AUC0-tlast , AUC from baseline to last measurable concentration; AUC, area under the plasma concentration curve; AUCnorm , AUC from baseline
to infinity normalized for dose/kg body weight; Cmax , maximum observed concentration; Cmax,norm , Cmax normalized to dose and body weight; PK,
pharmacokinetic; SD, standard deviation; t 1 , half-life; tmax , time to reach Cmax .
2
All dosing was under fed conditions.
a Median (range).
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Figure 4. Nifurtimox plasma concentrations for participants in study B receiving 4 × 30-mg tablets in the fasted or fed states (n =
35). Data are arithmetic mean and standard deviation. LLOQ, lower limit of quantitation.

[90%CI]) for nifurtimox under fed conditions versus
fasted conditions were 171% (154%-191%) for AUC
and 172% (154%-192%) for AUC0-tlast . Peak exposure
increased by a similar degree under fed conditions
(Cmax , 168% [150%-187%]; Figure 5). The 90%CIs of
all ratios (fed/fasted) did not lie within the 80%-125%
range, indicating a pronounced food effect. Food intake also reduced the rate of absorption of nifurtimox,
increasing median tmax by 1 hour (Table 3).

Safety
In study A, a total of 8 of the 12 subjects in group 1
(66.7%) and 9 of the 24 subjects in group 2 (37.5%)
reported at least 1 TEAE. Of the 36 subjects in study
B, 5 (13.9%) reported a TEAE (Table 4). All TEAEs
in both studies were considered drug related, except
for 1 mild headache (study B). All TEAEs resolved
completely, most within 1 day. Three individuals were
treated for vomiting and 2 for headache. The TEAEs

2 (5.6)
1 (2.8)

0
1 (2.8)
1 (2.8)
1 (2.8)
1 (2.9)
1 (2.9)
0
2 (5.7)

AUC0-tlast , AUC from baseline to last measurable concentration; AUC,
area under the concentration curve; CL/F, apparent total body clearance;
Cmax , maximum observed concentration; PK, pharmacokinetic; SD, standard deviation; t 1 , half-life; tmax , time to reach Cmax .
2

(B)

2 (8.3)
4 (16.7)
1 (4.2)
4 (16.7)

(A)

9 (37.5)
9 (37.5)

(range).

Totala
(n = 24)

a Median

Intervention E: 4
× 30-mg Tablets,
Fed
(n = 36)

2590 ± 547
2450 ± 519
48.4 ± 10.4
490 ± 163
4.0 (1.0-8.0)
3.24 ± 0.91

3 (8.6)
3 (8.6)

2

1590 ± 606
1490 ± 568
87.4 ± 35.0
295 ± 109
3.0 (0.5-6.1)
3.24 ± 1.15

Intervention D:
4 × 30-mg
Tablets, Fasted
(n = 35)

AUC, μg·h/L
AUC0-tlast , μg·h/L
CL/F, L/h
Cmax , μg/L
tmax , ha
t1 , h

Intervention E:
4 × 30-mg Tablets,
Fed (n = 35)
Study B

Parameter

Intervention D:
4 × 30-mg Tablets,
Fasted (n = 35)

Totala
(n = 36)

Table 3. Pharmacokinetic Parameters of Nifurtimox in Study B
(Mean ± SD; PK Analysis Set)a

1 (2.8)
2 (5.6)
1 (2.8)
3 (8.3)
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5 (13.9)
4 (11.1)
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Figure 5. AUC and Cmax for nifurtimox in plasma under fasting and fed conditions in study B. x, mean; horizontal line, median; box, IQR; error bars, data range to a maximum of 1.5 ×
IQR; open circle, data outlier. AUC, area under the plasma concentration curve; Cmax , maximum observed concentration; IQR,
interquartile range.

experienced by subjects in both studies were mild or
moderate in intensity, and there were no serious AEs
or TEAEs leading to discontinuation of nifurtimox.
The most common TEAEs in both studies were known
side effects of nifurtimox, including vomiting, nausea,
abdominal pain, and headache, and no notable differences in TEAEs between intervention groups in either
study were observed (Table 4). No procedure-related

1 (4.2)
4 (16.7)
1 (4.2)
1 (4.2)
1 (4.2)
1 (4.2)
0
3 (12.5)

Group 2

5 (20.8)
5 (20.8)
5 (20.8)
5 (20.8)
8 (66.7)
8 (66.7)

0
2 (16.7)
6 (50.0)
5 (41.7)
TEAE, treatment-emergent adverse event.
Data are n (%).
a Total number of individuals over both treatment periods.

Fasted Fed

0
2 (16.7)
3 (25.0)
3 (25.0)

Fasted Fed

0
0
4 (33.3)
4 (33.3)

0

0

4 (33.3)
4 (33.3)

100

7 (58.3)
7 (58.3)

200

Totala
(n = 12)

1000

Event

300

Intervention A: 4
× 30-mg Tablets
(n = 24)

400

Intervention B:
4 × 30 mg
Aqueous Slurry
(n = 12)

2000

500

Intervention A:
4 × 30-mg
Tablets
(n = 12)

Cmax (μg/L)

AUC (μg•h/L)

600

Group 1

3000

Study A

700

Table 4. Treatment-Emergent Adverse Events by Study and Intervention Sequence (Safety Analysis Set)

800

Any TEAE
Drug-related TEAE
Most common
TEAEs
Abdominal pain
Nausea
Vomiting
Headache

4000

Intervention C:
1 × 120-mg
Tablet
(n = 24)

900
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AEs were reported in either study, there were no notable
differences in abnormal laboratory test results between
formulations in either study, and there were no clinically
relevant changes in any laboratory parameter.

Discussion
We conducted 2 studies comparing the PK of a new nifurtimox 30-mg tablet that can be administered as an
aqueous slurry with that of the marketed 120-mg tablet,
and also examined the impact of food on nifurtimox
absorption. The studies demonstrated that when taken
after food, the new nifurtimox 30-mg tablet formulation
administered at a total dose of 120 mg is bioequivalent
to the standard 120-mg tablet both in terms of systemic
exposure and bioavailability. The 30-mg tablet is scored
for ease of division, so the availability of both dose levels will permit doses to be adjusted in relation to age and
body weight in increments of 15, 30, 60, and 120 mg.
Furthermore, the option to administer the drug as an
aqueous slurry will facilitate treatment of very young
patients and individuals of any age who find it difficult
to swallow tablets.
In the context of the current clinical development
program for pediatric nifurtimox, target daily dosing
is 8-10 mg/kg in adolescents weighing >40 kg, and
10-20 mg/kg in children younger than 10 years of age
weighing < 40 kg. The total daily dose is typically divided into 3 doses administered every 8 hours.18 Dose
adjustment according to body weight is frequently unwieldy and inaccurate when a 120-mg tablet is the
only dose available. Administration of quarter tablets
is the only option when trying to optimize dose without exceeding recommended levels, and may need to be
readjusted if patients lose weight while on treatment.18
Moreover, dosing may become unsafe when the accuracy of dose adjustment in young children or infants
depends on dividing a tablet with precision. Dose adjustment will be greatly facilitated when 15-mg dose increments can be deployed.
The option to disperse nifurtimox tablets in an aqueous slurry also facilitates dose adjustment, and confers
a useful safety advantage, avoiding possible bronchial
obstruction in infants following unintentional aspiration of a tablet. Foreign-body aspirations occur mainly
in children but are also reported among the elderly, and
it has been estimated that 7% of all such aspirations
are medicinal pills.20,21 Accordingly, administration of
medicinal pills should be avoided in high-risk patients
such as infants and those with swallowing disorders.21
When dispersed as an aqueous slurry and administered
to individuals after food, the concentration of nifurtimox in plasma emulated that achieved by administering four 30-mg tablets, and overall systemic exposure to
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nifurtimox was essentially the same for both modes of
administration.
The current label stipulates that nifurtimox should
be taken after meals,18 which may help to mitigate
gastrointestinal TEAEs. Although this places an additional restriction on an already complex dosing
regimen, our studies show that it has a major impact
on absorption of the drug based on the striking effect
of food on bioavailability. It is known that food can
have such effects for a variety of reasons, such as interacting physically or chemically with the drug substance,
delaying gastric emptying, stimulating bile release, and
changing the pH within the gastrointestinal tract and
altering its blood flow.22,23 For this reason, the US Food
and Drug Administration (FDA) recommends evaluation of bioequivalence following ingestion of a 800- to
1000-kcal meal in which around 50% of the total calories come from fat (as was employed here) to maximize
the potential for demonstrating a food effect.22
In our analysis, food intake seemed to slow the absorption of nifurtimox slightly based on the change in
time from dosing to peak plasma concentration (median tmax increased from 3 to 4 hours). Total systemic exposure to nifurtimox was also ≈71% greater
after food than in a fasted state. As a poorly soluble drug, prolonged gastric residence of nifurtimox
may have contributed to this improvement in oral
bioavailablilty. The underlying mechanism for this is
unclear, but could relate to enhanced solubility owing
to the presence of bile acids, longer residence in the
intestine and/or increased splanchnic blood flow after
food ingestion.22 Nevertheless, systemic exposure in response to a 120-mg dose of nifurtimox was remarkably
consistent across both studies providing that the dose
was administered after food.
Historical nifurtimox PK data have been obtained in
2 small studies. One study in 7 healthy volunteers, each
receiving a single oral dose of nifurtimox 15 mg/kg,
determined the elimination t 1 to be 2.95 hours and tmax
2
to be 2.24 hours.10 A subsequent study investigated nifurtimox PK characteristics in 7 patients with chronic
renal failure receiving regular hemodialysis.24 AUC
and Cmax for nifurtimox, also after a single oral dose
of nifurtimox 15 mg/kg, were 70%-75% higher in patients with renal failure than in the healthy volunteers
(AUC, 9510 vs 5430 μg·h/L, respectively; Cmax , 1290 vs
751 μg/L, respectively; values in patients on dialysis
were determined on a nondialysis day).10,24 No significant differences in t 1 or tmax were seen between the 2
2
patient groups. These observed differences in exposure
and in Cmax between the studies were similar in magnitude to the differences in these parameters between fed
and fasting patients in our studies. As fed/fasting status
was not disclosed in the report on patients with renal
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failure, it may be the case that the greater systemic
availability in these patients was caused by a food
effect.24 Were the differences attributable to poorer
drug clearance, a longer elimination half-life than in
healthy individuals might also have been expected in
those with renal failure.
The absorption and elimination profiles of nifurtimox in these studies following oral ingestion
under fasted conditions were similar to the findings
under fasting conditions in the current study in patients with Chagas disease. Although the Cmax in
healthy controls (751 μg/L)10 was higher than that
observed in plasma here (277 μg/L), the dose employed
(15 mg/kg) was considerably higher than that administered in our studies (120 mg total dose or up to
2 mg/kg). As well as differences in dose, methodological differences between the historical studies and the
current study generally impede their direct comparison.
Nifurtimox was well tolerated in the current studies,
whether administered as a single 120-mg tablet, as four
30-mg tablets, or as an aqueous slurry made from four
30-mg tablets and also when given under fed or fasted
conditions; there were no new safety or tolerability
findings. The most common TEAEs observed during
the studies were gastrointestinal disorders (vomiting,
nausea, and abdominal pain) and headache, which
are known side effects of nifurtimox.4 All nifurtimoxrelated TEAEs were mild or moderate in intensity and
resolved, mostly within a day, as has previously been
reported with the drug.15,25,26 Although it is difficult
to draw conclusions about safety and tolerability from
relatively small, single-dose studies, the frequency
and type of TEAEs were broadly the same across all
intervention groups, and no severe or serious events
were reported. The overall rate of TEAEs was greater
in study A than in study B, but there is no obvious
clinical explanation for this difference; it may be attributable to relatively small sample sizes. In terms of
drug-related safety and tolerability, taking nifurtimox
after food may reduce the likelihood of gastrointestinal
TEAEs compared with taking them when fasting;
however, these events were infrequent in our study, so
no conclusions can be drawn.
We followed FDA guideline recommendations for
the bioequivalence study and took a comparable approach for the food-effect study. Our studies employed
randomized, 2-period crossover designs with an intervening washout of at least 5 half-lives (equating to
<1 day for nifurtimox, whereas our studies included a
washout of ≥5 days). The smallest group in our studies
was 12 individuals, the threshold sample size advocated
in the guidelines, with twice that number being enrolled
in the demonstration of bioequivalence. The test conditions (fasting period, diet, fluid intake, activity levels,
time of ingestion, etc.) and sampling conditions all fol-
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lowed guideline recommendations, as did the fat and
calorie content of the standard meal. It should be noted
that the effect of food on the PK of nifurtimox reported
here may be less marked among individuals infected
with Chagas disease, who do not typically eat the type
of guideline-recommended high-fat, high-calorie meals
used in our study. For this reason, a clinical study is underway to investigate the influence on nifurtimox PK
of diets that are representative of those among children
typically encountered in routine clinical practice (eg, diets rich in dairy products).
After food intake, 4 of the new nifurtimox 30-mg
tablets were found to be bioequivalent to the currently
marketed nifurtimox 120-mg tablet in men and women
with chronic Chagas disease. In addition, oral administration as an aqueous slurry was found to be equivalent
to ingestion of four 30-mg nifurtimox tablets, offering
the possibility of accurate age- and body weight-based
dosing of nifurtimox in a format that is simple to prepare and that is manageable for individuals who may
choke on whole tablets, such as infants and very young
children. Nifurtimox, given either as a single 120-mg
dose or as four 30-mg tablets, was well tolerated, and no
new safety signals were observed. With 2 dose strengths
that permit administration in 15-mg increments, and
the option to administer nifurtimox as a slurry, a complex dosing schedule can be translated into a practical
regimen for use irrespective of age group in an outpatient setting.
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